drugset

drugset / Trial / NCT00702780

Progression Delaying Effect of Escitalopram in Alzheimer's Disease

NCT00702780 ↗

Completed 74 enrolled Seoul National University Hospital H. Lundbeck A/S · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aimed to test whether escitalopram would slow the brain atrophy in patients with mild to moderate AD over the 52-week period.

Timeline

Start: 2008-11
Primary completion: 2011-09
Completion: 2011-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Escitalopram	Small molecule	20 mg	Oral

Indications